semaglutide bone mineral density GLP-1s may increase risk of osteoporosis and gout, new research finds GLP-1 Agonists and Orthopedic Surgery:

Countries within the EU evaluate semaglutide individually through their national medicines agencies, resulting in fragmented access compared to the unified FDA approval model in the United States

At lower doses, study participants lost an average 21.4 per cent to 16 per cent of their body weight

Developmental regulation of circulating insulin-like growth factor-binding proteins in normal pregnancies and in pre-eclampsia

Sleep and recovery often improve within weeks, while body composition and energy levels noticeably shift within 2 to 3 months

A growing body of evidence supports the use of multi-agent regimens combining RAASi, SGLT2i, GLP-1 RAs, and ns-MRAs

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet